Natco settles patent litigation in the U.S.

Pharma major can launch Carfilzomib

May 30, 2019 10:44 pm | Updated 10:44 pm IST - HYDERABAD

Drug maker Natco Pharma has reached a settlement with Onyx Therapeutics Inc. on a patent litigation related to generic versions of anti-cancer drug Kyprolis (10mg, 30mg and 60mg).

The parties have reached an agreement and the district court case has been dismissed. By virtue of the settlement, Natco and its U.S. marketing partner Breckenridge have been granted a licence permitting the launch of their generic, Carfilzomib, on a date held as confidential, in 2027 or sooner depending on certain occurrences.

The parties cannot make further comment as to the terms of the settlement agreement, a statement from Natco Pharma on Thursday said. Kyprolis, which is used to treat patients with relapsed or refractory multiple myeloma, had sales of $586 million for the year ended December 2018 in the U.S.

Marketing exclusivity

NATCO believes that its 10 mg ANDA is the sole first to file and could be eligible for 180-day marketing exclusivity for the 10 mg strength under certain circumstances, the release said. Shares of the Hyderabad-headquartered firm closed at ₹515.90 apiece, down 1.45%, on BSE.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.